Spinoff of Prima Plastics run by the founder's son, with the founder transferring shares and parent guaranteeing its debt; June margins jumping to 10% suggest improving prospects.

SP Refractories trades at ~6.4x earnings with a repaired balance sheet and niche high-alumina refractory cement, but falling sales and profit driven by price-cost gap leave durable growth unproven; watchlist only.

India's irrigation expansion insulated food security but created two interlocking crises: unsustainable groundwater depletion from free/subsidised farm power, and financially gutted state DISCOMs — constraints that will shape any company operating in this space.

India's trade is carried overwhelmingly on foreign-flagged ships, draining freight income; the new ₹69,725 crore shipbuilding package and Merchant Shipping Act give domestic shipbuilding a policy-backed structural opportunity.

Sheela Foam is India’s branded mattress leader whose record profits and first dividend are obscured by a debt-funded Kurlon acquisition; as the accounting drag reverses, the 60%-crashed stock looks mispriced.

Intelligent eyewear marks a third era for Indian optical retail, shifting power to consumer and technology pull. Opticians risk higher turnover without proportionately higher profit as Meta-EssilorLuxottica vertical integration captures the economics, though fitting, optometry and trust remain their moat.

Despite optically cheap ~12x earnings, Peshwa Wheat's weak cumulative operating cash flow, promoter-linked supplier/customer, high receivables, and tax/compliance issues outweigh the apparent cheapness; avoid the IPO.

Europe may restrict metal scrap exports to India from May 2027, forcing Indian metal companies to source elsewhere, raising raw material costs and increasing energy use.

China's household and state gold buying is putting a floor under bullion, while India's record import duty has crushed official imports, created a domestic discount and grey market, and may force a policy reversal.

Pharma is at record highs yet still the asymmetric bet because it never had speculative froth; the winners are branded generics, diagnostics and CDMOs, not commodity US generics that dominate the index.

Author argues the AI data-centre connectivity pivot (new wholly-owned subsidiary, Neuralis high-density fiber portfolio) could be a structural shift, but the multi-fold re-rating may already price in years of growth ahead of execution.

Scimplify is an asset-light advanced materials and specialty chemicals company solving India's trust and coordination gap, positioning it to capture the global shift away from China and patent expiries, with rapid ARR growth.

IRDAI's proposed commission caps threaten PB Fintech's revenue as an insurance distributor; some sale revenues could roughly halve, though impact depends on product mix and cost cuts.

India's record 88.7% crude import dependence and falling domestic output leave it vulnerable; strategic reserves are underfunded, so policy must prioritize reserves, electrification, and deepwater technology.

Core ATBS and IBB businesses have durable moats and are cash-generative, but heavy capex into Veeral Organics and antioxidants has yet to earn returns, so profit growth lags capital invested; the stock's re-rating now hinges on execution of new plants.

Bull case rests on a leading advisor distribution network, ~38% three-year revenue CAGR and recurring renewal commissions; offset by persistent losses, negative operating cash flow, heavy advisor spend and competition that may delay profitability.

Premium weekend getaway demand is driving hotel chains to acquire boutique resorts, but operators face thin margins and difficulty filling rooms Monday-Thursday, making the segment risky.

China's vinblastine-yeast breakthrough extends its grip on medicine's molecular foundations, but Western de-risking hands India a real opening: it is the second-largest magnet for reshoring capex, and BioE3 could move it up the value chain — if it builds capacity and patents.

Passed on almost all of its estimated 10-12% cost increase, limiting margin hit; can reduce channel schemes to rebuild margins if costs stabilize.

Could pass on only ~5% of planned 13% cost increase, causing PBT to fall ~24%; higher promotions to regain share added margin pressure.

India's strategy of exporting UPI as a neutral public good and settling trade in rupees via SRVA lets it gain global payments influence and cut dollar dependence without picking sides, though US pressure on zero merchant fees and BRICS overreach are key risks.

ITC screens cheap on trailing P/E, dividend yield and cash, but those figures predate the Feb 2026 cigarette tax reset; cigarette PBIT fell 35%, while FMCG-Others is the real sunrise engine. Watch at ₹266, reassess near ₹200/₹180.

OCS revenue has scaled from zero to over $100M a quarter, moving the product into quarterly-results territory, but early manufacturing experience may not be a durable moat once rivals qualify competing designs.

A growing OCS market and stable market share for today's suppliers are separate propositions; adoption depends on how many electrical switching stages can be removed and how well the optical circuits are utilized.

Epack is a beaten-down AC ODM whose profits collapsed on weak demand and fixed costs, but AP's 50% subsidy, rising Sri City utilisation, backward integration, and non-AC/Hisense expansion could revive operating leverage and returns.

Epack is India's second-largest room-AC ODM; near-term profit collapsed on reverse operating leverage, but Andhra Pradesh subsidies, backward integration, non-AC diversification, and Sri City utilisation recovery can improve returns.

NSE is a tollbooth-like market infrastructure with a network-effect moat, capital-light economics and high margins, positioned to capture India's shift from savings to investing as household financialisation compounds.

NSE is a tollbooth-like market infrastructure benefiting from India's financialisation, with strong network effects, high margins and multiple monetisation avenues; risks are regulatory intervention, cyclical volumes and premium valuation.

Textile waste is a vast, unregulated stream with no EPR, no recycled-fibre HSN code and zero commercial chemical recycling capacity; the case rests on pending regulation and the value locked in sorting clean cotton out of downcycling.

India's AI push subsidizes GPU supply but neglects the consumption side; cheap consumer AI tokens bundled by carriers like Jio could drive mass adoption and prevent the market from defaulting to Chinese tokens.

Atul’s heavy capex is largely behind it and idle capacity can support more sales; Q1 FY27 profit growth and falling cash capex may drive operating leverage, but at ~23x earnings much of recovery may already be priced in.

India's nuclear opening is only partial: private firms can finance, build and now legally own reactors, but fuel, waste, technology and licensing stay with the state, so bankable fully private projects remain distant.

China is de-dollarising Africa through CIPS, yuan trade and debt, eroding dollar-sanctions leverage; India risks being sidelined and should stop mimicking China, instead leveraging its deficit position to internationalise the rupee.

Syngene is a watch: the moat is strong in embedded/regulated programmes but weak in commoditised research, and Bayview/Mangalore utilisation must improve; at ₹369 the central case offers only 10–13% annual price appreciation to March 2031.

Author argues Arman grows faster (25-30% annually) with better return ratios than PSU lenders, and its habit of raising equity at high P/B lifts book value — making it the superior long-term compounder, now his largest holding.

Same cheap-PSU thesis as PFC: low valuation, 4-5% dividend yield plus 10-12% earnings growth; author bought on management's 18% growth guidance, which disappointed at 12%.

Bought for extremely cheap valuations with PSU bearishness creating the opportunity; author expects 4-5% dividend yield plus 10-12% EPS growth from retained earnings, but eventually sold out.

Positioned as a services contractor that captures spending under the government's Rs 84,084 crore Samudra Manthan offshore exploration push, with four engines: oilfield services, high-margin mechanised coal handling, dollar-earning offshore manpower, and promoter oil fields via reverse merger.

Asset-owning hotel company using Brigade Group's in-house development to build hotels below market cost, doubling keys to ~3,300 and shifting mix to luxury/upscale by FY31, which should roughly double ADR and grow revenue to ~Rs 2,300 Cr by FY32.

Cohance shows early Stage-2 turnaround evidence (new orders, commercial supply, Sapala growth), but at ₹438 its depressed trailing earnings and uncertain recovery don't justify the price; verdict is watch, not attractive.

India risks importing subsidised Chinese brain implants, repeating the API dependency; instead it should exploit its lab strength to dominate affordable non-invasive wearable BCI (EEG plus AI), though weak patent and neural-data privacy laws hold it back.

BLS has a durable regulatory moat in visa processing, sticky 7-year government contracts, asset-light low-debt operations, and structural growth; appears discounted if free cash flow grows 11% over the next decade.

Under 20x mid-cycle with no net debt, Uniparts is a system supplier to Deere-class OEMs whose contractual, 403-day inventory still converts 94% of operating profit to cash, making its earnings durable.

Happy Forgings is a compounder rather than a cyclical: 21% revenue CAGR and a stable 27–31% margin band with 90% of output machined, so a cyclical metal-conversion lens misprices it.

Cheap at under 20x mid-cycle, but the purest truck-cycle forger carries the heaviest balance sheet: 5.9x net debt to trough operating profit, 2.3x interest cover and mid-capex, so its debt persists if truck builds pause.

India's coal consumption won't enter a lasting decline because heavy industries like steelmaking rely on coal for raw heat and chemical processing, locking in decades of demand even as clean power meets new grid demand.

Hindalco is building a ₹2,000-crore secondary copper and e-waste recycling plant in Gujarat, scaling to 200 KTPA, designed for complex low-grade scrap and precious metal recovery, positioning it for India's EPR-driven recycling mandates.

Named as a natural landing zone for factory work displaced from China by the BIOSECURE Act, with the market rewarding its predictable generic cash flows and factory execution.

Global pharma has split Asia's roles: China invents molecules, India manufactures them. The BIOSECURE Act and China's price controls push Western factory work to Indian CDMOs, and the market pays a premium for India's predictable supply.

Crescentis has pivoted from a dormant listed shell into an active NBFC lending franchise; headline FY26 losses are misleading, masking positive core cash operating profit of ₹1.68 Cr and a lending-inflection that drove ₹7.82 Cr PAT in Q1 FY27.